Blog Band - Page 21 of 299

27

Aug 2025

Abbott Receives the European CE Mark for Esprit BTK System to Treat Peripheral Artery Disease Below the Knee

Shots: Abbott has received European CE Mark approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System to treat people with peripheral artery disease (PAD) below the knee (BTK) Esprit…

27

Aug 2025

NEWS

Regeneron Reports P-III (NIMBLE) Trial Data of Cemdisiran for Generalized Myasthenia Gravis (gMG)

Shots: The P-III NIMBLE trial enrolled adults with symptomatic gMG & anti-AChR antibodies, randomizing them to cemdisiran (600mg, SC, Q12W, n=64), cemdi-poze (SC, Q4W, n=67), or PBO (n=59), with completion…

27

Aug 2025

NEWS

Gilead Reports the EC’s Approval of Yeytuo (Lenacapavir) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV in Individuals at Risk

Shots: Approval was based on P-III (PURPOSE 1 & PURPOSE 2) trials of Yeytuo vs Truvada, where PURPOSE 1 showed 0 infections & 100% risk reduction in 2134 women, while…

27

Aug 2025

NEWS

Bio-Thera Secures the EC’s Approval for Usymro (Biosimilar, Stelara)

Shots: The EC has approved Usymro (BAT2206), a biosimilar version of J&J’s Stelara (ustekinumab) for all indications of the reference product In Oct 2024, Bio-Thera & Gedeon Richter entered a…

26

Aug 2025

INSIGHTS+

New Drug Designations: July 2025

Shots:    PharmaShots’ Designation Report offers a concise overview of the latest drug and device designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada, and NMPA. The…

26

Aug 2025

NEWS

BioArctic and Novartis sign agreement for BrainTransporter ~$802M

Shots: BioArctic has entered into an option, collaboration, and license agreement with Novartis to develop a neurodegeneration treatment using BrainTransporter As per the deal, BioArctic receives $30M upfront and could earn up to…

26

Aug 2025

VIDEO

LIFE SCIENCES | DAILY NEWS | AUG 26, 2025 | PHARMASHOTS

26

Aug 2025

NEWS

Mannkind Acquires Scpharmaceuticals to Strengthen Its Cardiometabolic and Lung Diseases Portfolio

Shots: MannKind has signed definitive merger agreement to acquire ScPharmaceuticals Under the merger agreement, MannKind will launch a tender offer to acquire all outstanding scPharmaceuticals shares for $5.35 per share…

26

Aug 2025

NEWS

Merz Therapeutics Enrolls First Patients in P-III Studies Evaluating Xeomin for Migraine Prevention

Shots: Merz Therapeutics has enrolled the first patients in two global P-III studies, MINT-E (episodic migraine, ~990 pts) and MINT-C (chronic migraine, ~780 pts), evaluating the efficacy and safety of…

26

Aug 2025

NEWS

Abbott Reports the Approval for its Denosumab Biosimilar in Thailand

Shots: Abbott has secured regulatory approval for its denosumab biosimilar in Thailand, increasing access to advanced treatments for osteoporosis and cancer-related bone loss Denosumab is a mAb that works by…

Abbott Receives the European CE Mark for Esprit BTK System to Treat Peripheral Artery Disease Below the Knee

Regeneron Reports P-III (NIMBLE) Trial Data of Cemdisiran for Generalized Myasthenia Gravis (gMG)

Gilead Reports the EC’s Approval of Yeytuo (Lenacapavir) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV in Individuals at Risk

Bio-Thera Secures the EC’s Approval for Usymro (Biosimilar, Stelara)

New Drug Designations: July 2025

BioArctic and Novartis sign agreement for BrainTransporter ~$802M

LIFE SCIENCES | DAILY NEWS | AUG 26, 2025 | PHARMASHOTS

Mannkind Acquires Scpharmaceuticals to Strengthen Its Cardiometabolic and Lung Diseases Portfolio

Merz Therapeutics Enrolls First Patients in P-III Studies Evaluating Xeomin for Migraine Prevention

Abbott Reports the Approval for its Denosumab Biosimilar in Thailand

Contact US

OUR INFORMATION

FOLLOW US